Aprea Therapeutics, Inc.
APRE
$0.79
-$0.04-5.22%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 3.30K | 1.80K | 118.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 3.30K | 1.80K | 118.10K |
| Cost of Revenue | 2.46M | 1.61M | 1.01M | 1.64M | 1.91M |
| Gross Profit | -2.46M | -1.61M | -1.01M | -1.64M | -1.79M |
| SG&A Expenses | 1.57M | 1.82M | 1.64M | 1.48M | 1.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.03M | 3.43M | 2.65M | 3.12M | 3.51M |
| Operating Income | -4.03M | -3.43M | -2.64M | -3.12M | -3.39M |
| Income Before Tax | -3.59M | -3.29M | -2.46M | -2.97M | -3.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.59M | -3.29M | -2.46M | -2.97M | -3.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.59M | -3.29M | -2.46M | -2.97M | -3.24M |
| EBIT | -4.03M | -3.43M | -2.64M | -3.12M | -3.39M |
| EBITDA | -4.03M | -3.43M | -2.64M | -3.11M | -3.38M |
| EPS Basic | -0.07 | -0.22 | -0.32 | -0.47 | -0.53 |
| Normalized Basic EPS | -0.04 | -0.14 | -0.20 | -0.29 | -0.33 |
| EPS Diluted | -0.07 | -0.22 | -0.32 | -0.47 | -0.53 |
| Normalized Diluted EPS | -0.04 | -0.14 | -0.20 | -0.29 | -0.33 |
| Average Basic Shares Outstanding | 53.48M | 14.69M | 7.69M | 6.37M | 6.08M |
| Average Diluted Shares Outstanding | 53.48M | 14.69M | 7.69M | 6.37M | 6.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |